Last 7 days
4.9%
Last 30 days
33.0%
Last 90 days
2.5%
Trailing 12 Months
58.6%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MDT | 109.8B | 30.8B | -9.29% | -16.09% | 26.95 | 3.57 | -3.19% | -17.32% |
ISRG | 107.6B | 6.4B | 1.94% | 34.00% | 82.01 | 16.73 | 8.89% | -20.19% |
EW | 49.3B | 5.5B | -7.47% | -19.49% | 33.14 | 8.97 | 2.68% | -3.23% |
ALGN | 21.8B | 3.7B | -12.40% | 0.13% | 69.2 | 5.89 | -8.10% | -55.37% |
HOLX | 19.5B | 4.1B | -8.55% | 1.55% | 25.84 | 4.8 | -24.76% | -51.48% |
MID-CAP | ||||||||
PEN | 11.8B | 884.6M | 9.37% | 108.01% | 1.8K | 13.39 | 13.08% | 200.12% |
NVST | 5.4B | 2.6B | -14.32% | -23.28% | 25.47 | 2.1 | 1.47% | -29.43% |
CNMD | 3.6B | 1.1B | -5.65% | 2.15% | -38.56 | 3.29 | 7.68% | -238.55% |
LIVN | 2.4B | 1.0B | -8.50% | -35.10% | -28.78 | 2.25 | 1.66% | 19.79% |
TMDX | 2.4B | 119.1M | -8.56% | 141.99% | -83.21 | 19.75 | 204.77% | 39.65% |
SMALL-CAP | ||||||||
ESTA | 1.6B | 169.8M | -7.71% | 2.34% | -19.37 | 9.27 | 25.95% | -102.42% |
AVNS | 1.1B | 814.3M | -18.92% | -16.55% | 25.06 | 1.37 | 6.96% | 121.89% |
BLFS | 1.0B | 163.2M | 33.03% | 58.59% | -6.9 | 6.19 | 17.84% | -885.82% |
INGN | 255.0M | 369.0M | -17.13% | -57.43% | -2.84 | 0.69 | 5.00% | -353.73% |
SDC | 54.4M | 438.9M | -7.48% | -74.66% | -0.63 | 0.12 | -25.59% | -12.50% |
Income Statement (Last 12 Months) | ||||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Revenue | 0.9% | 163,242,000 | 161,759,000 | 154,805,000 | 147,858,000 | 138,529,000 |
S&GA Expenses | 7.3% | 23,150,000 | 21,570,000 | 20,361,000 | 19,149,000 | 16,876,000 |
R&D Expenses | 2.5% | 15,169,000 | 14,798,000 | 14,205,000 | 13,999,000 | 13,616,000 |
EBITDA | -4.9% | -104,198,000 | -99,319,000 | -28,579,000 | - | - |
EBITDA Margin | -0.2% | -0.67 | -0.67 | -0.21 | - | - |
Earnings Before Taxes | -4.1% | -150,784,000 | -144,827,000 | -112,837,000 | -107,190,000 | -35,573,000 |
EBT Margin | -0.6% | -0.72 | -0.72 | -0.25 | - | - |
Interest Expenses | 69.3% | 992,000 | 586,000 | 682,000 | 573,000 | 543,000 |
Net Income | -4.8% | -146,453,000 | -139,805,000 | -105,322,000 | -95,286,000 | -14,856,000 |
Net Income Margin | -5.7% | -0.67 | -0.64 | -0.10 | - | - |
Free Cahsflow | -2.6% | -24,622,000 | -24,001,000 | -22,458,000 | - | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Assets | -0.8% | 446 | 450 | 488 | 470 | 544 |
Current Assets | -4.1% | 133 | 138 | 136 | 118 | 119 |
Cash Equivalents | -1.7% | 19.00 | 19.00 | 27.00 | 24.00 | 59.00 |
Inventory | 18.4% | 41.00 | 35.00 | 34.00 | 33.00 | 30.00 |
Net PPE | 10.4% | 26.00 | 24.00 | 22.00 | 19.00 | 18.00 |
Goodwill | 0% | 225 | 225 | 225 | 225 | 225 |
Liabilities | 2.7% | 88.00 | 86.00 | 79.00 | 58.00 | 65.00 |
Current Liabilities | 6.1% | 47.00 | 45.00 | 37.00 | 33.00 | 35.00 |
Long Term Debt | 248.0% | 26.00 | 8.00 | 7.00 | - | - |
LT Debt, Current | -31.1% | 1.00 | 2.00 | 2.00 | 1.00 | 1.00 |
LT Debt, Non Current | -0.4% | 24.00 | 24.00 | 24.00 | 6.00 | 6.00 |
Shareholder's Equity | -1.7% | 358 | 364 | 408 | 412 | 479 |
Retained Earnings | -5.6% | -260 | -246 | -194 | -184 | -112 |
Additional Paid-In Capital | 1.2% | 619 | 612 | 604 | 598 | 591 |
Shares Outstanding | 1.1% | 43.00 | 43.00 | 43.00 | 43.00 | 42.00 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Cashflow From Operations | 61.4% | -3.28 | -8.49 | -17.12 | -16.53 | -14.34 |
Share Based Compensation | 7.8% | 27.00 | 25.00 | 23.00 | 21.00 | 18.00 |
Cashflow From Investing | 8.9% | -52.92 | -58.12 | -45.76 | -31.89 | -11.03 |
Cashflow From Financing | -2.3% | 16.00 | 16.00 | 15.00 | -3.63 | -4.17 |
97.7%
86.2%
63.1%
Y-axis is the maximum loss one would have experienced if BioLife Solutions was unfortunately bought at previous high price.
16.6%
47%
16.9%
12.4%
FIve years rolling returns for BioLife Solutions.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-05-22 | AMERIPRISE FINANCIAL INC | reduced | -14.7 | 397,895 | 20,968,900 | 0.01% |
2023-05-18 | NEW YORK STATE COMMON RETIREMENT FUND | added | 2.55 | 1,451,000 | 7,884,000 | 0.01% |
2023-05-18 | JPMORGAN CHASE & CO | added | 0.31 | 1,462,000 | 8,815,000 | -% |
2023-05-17 | Thrivent Financial for Lutherans | added | 2.11 | 1,375,000 | 7,614,000 | 0.02% |
2023-05-16 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | new | - | 358,658 | 358,658 | -% |
2023-05-16 | Meros Investment Management, LP | added | 4.00 | 955,704 | 4,888,700 | 2.78% |
2023-05-16 | FRED ALGER MANAGEMENT, LLC | reduced | -2.66 | 5,875,300 | 41,873,400 | 0.22% |
2023-05-16 | Baker Avenue Asset Management, LP | unchanged | - | 3,578 | 21,924 | -% |
2023-05-16 | Rockefeller Capital Management L.P. | sold off | -100 | -90,000 | - | -% |
2023-05-15 | KENFARB & CO. | unchanged | - | 17,800 | 108,750 | 0.10% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 09, 2023 | vanguard group inc | 5.77% | 2,466,931 | SC 13G/A | |
Jan 26, 2023 | blackrock inc. | 12.8% | 5,477,126 | SC 13G/A | |
Jan 20, 2023 | blackrock inc. | 12.8% | 5,477,126 | SC 13G/A | |
Jan 11, 2023 | millennium management llc | 1.6% | 670,202 | SC 13G/A | |
Jul 08, 2022 | blackrock inc. | 11.5% | 4,893,203 | SC 13G | |
Jun 22, 2022 | millennium management llc | 5.1% | 2,166,344 | SC 13G | |
Feb 09, 2022 | vanguard group inc | 5.16% | 2,147,258 | SC 13G | |
Feb 01, 2022 | blackrock inc. | 8.8% | 3,655,057 | SC 13G/A | |
Nov 01, 2021 | villiger walter | 4.86% | 1,979,226 | SC 13D/A | |
Sep 09, 2021 | blackrock inc. | 11.1% | 4,528,723 | SC 13G |
Date Filed | Form Type | Document | |
---|---|---|---|
May 25, 2023 | 4 | Insider Trading | |
May 23, 2023 | 4 | Insider Trading | |
May 19, 2023 | 4/A | Insider Trading | |
May 19, 2023 | 8-K | Current Report | |
May 18, 2023 | 4 | Insider Trading | |
May 17, 2023 | 4 | Insider Trading | |
May 17, 2023 | 4 | Insider Trading | |
May 17, 2023 | 4 | Insider Trading | |
May 17, 2023 | 4 | Insider Trading | |
May 17, 2023 | 4 | Insider Trading |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-05-25 | Mathew Aby J. | acquired | 20,600 | 2.06 | 10,000 | evp & chief scientific officer |
2023-05-25 | Mathew Aby J. | sold | -223,300 | 22.33 | -10,000 | evp & chief scientific officer |
2023-05-24 | Mathew Aby J. | acquired | 20,600 | 2.06 | 10,000 | evp & chief scientific officer |
2023-05-24 | Mathew Aby J. | sold | -221,400 | 22.14 | -10,000 | evp & chief scientific officer |
2023-05-22 | Casdin Partners Master Fund, L.P. | bought | 545,790 | 21.8552 | 24,973 | - |
2023-05-19 | Casdin Partners Master Fund, L.P. | bought | 1,127,430 | 22.5486 | 50,000 | - |
2023-05-18 | Casdin Partners Master Fund, L.P. | bought | 652,692 | 21.7564 | 30,000 | - |
2023-05-17 | Rice Michael | sold | -701,326 | 21.04 | -33,333 | ceo |
2023-05-17 | Casdin Partners Master Fund, L.P. | bought | 639,446 | 21.2957 | 30,027 | - |
2023-05-16 | Wichterman Troy | sold | -2,659 | 19.41 | -137 | chief financial officer |
Unaudited Condensed Consolidated Statements of Operations - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2023 | Mar. 31, 2022 | |
Revenue | $ 37,703 | $ 36,220 |
Costs and operating expenses: | ||
General and administrative | 14,842 | 11,530 |
Sales and marketing | 6,471 | 4,891 |
Research and development | 4,152 | 3,781 |
Intangible asset amortization | 1,459 | 2,863 |
Acquisition costs | 0 | 11 |
Change in fair value of contingent consideration | 720 | (3,335) |
Total operating expenses | 51,308 | 44,187 |
Operating loss | (13,605) | (7,967) |
Other expense: | ||
Interest expense, net | (411) | (184) |
Other income | 394 | 131 |
Total other expense, net | (17) | (53) |
Loss before income tax (expense) benefit | (13,622) | (8,020) |
Income tax (expense) benefit | (92) | 599 |
Net loss | (13,714) | (7,421) |
Net loss attributable to common shareholders: | ||
Basic and Diluted | $ (13,714) | $ (7,421) |
Basic and Diluted (in dollars per share) | $ (0.32) | $ (0.18) |
Weighted average shares used to compute loss per share attributable to common shareholders: | ||
Basic and Diluted (in shares) | 43,027,612 | 42,014,055 |
Product [Member] | ||
Revenue | $ 31,593 | $ 30,388 |
Costs and operating expenses: | ||
Cost of goods and services | 18,397 | 20,384 |
Service Revenue [Member] | ||
Revenue | 4,471 | 3,090 |
Costs and operating expenses: | ||
Cost of goods and services | 3,891 | 2,145 |
Rental Revenue [Member] | ||
Revenue | 1,639 | 2,742 |
Costs and operating expenses: | ||
Cost of goods and services | $ 1,376 | $ 1,917 |
Unaudited Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 19,105 | $ 19,442 |
Restricted cash | 31 | 31 |
Available-for-sale securities, current portion | 35,780 | 43,260 |
Accounts receivable, trade, net of allowance for doubtful accounts of $956 and $739 as of March 31, 2023 and December 31, 2022, respectively | 30,343 | 33,936 |
Inventories | 41,329 | 34,904 |
Prepaid expenses and other current assets | 6,201 | 6,879 |
Total current assets | 132,789 | 138,452 |
Assets held for rent, net | 9,005 | 9,064 |
Property and equipment, net | 26,100 | 23,638 |
Operating lease right-of-use assets, net | 15,592 | 15,292 |
Financing lease right-of-use assets, net | 242 | 272 |
Long-term deposits and other assets | 284 | 281 |
Available-for-sale securities, long-term | 2,019 | 1,332 |
Equity investments | 5,069 | 5,069 |
Total intangible assets, net | 30,629 | 32,088 |
Goodwill | 224,741 | 224,741 |
Total assets | 446,470 | 450,229 |
Current liabilities: | ||
Accounts payable | 15,525 | 15,367 |
Accrued expenses and other current liabilities | 10,701 | 9,782 |
Sales taxes payable | 4,585 | 4,151 |
Warranty liability | 8,895 | 8,312 |
Lease liabilities, operating, current portion | 2,906 | 2,860 |
Lease liabilities, financing, current portion | 161 | 158 |
Debt, current portion | 1,250 | 1,814 |
Contingent consideration, current portion | 3,296 | 2,138 |
Total current liabilities | 47,319 | 44,582 |
Contingent consideration, long-term | 1,880 | 2,318 |
Lease liabilities, operating, long-term | 15,114 | 14,962 |
Lease liabilities, financing, long-term | 95 | 126 |
Debt, long-term | 23,692 | 23,793 |
Deferred tax liabilities | 263 | 250 |
Other long-term liabilities | 0 | 10 |
Total liabilities | 88,363 | 86,041 |
Commitments and contingencies (Note 12) | ||
Shareholders’ equity: | ||
Preferred stock, $0.001 par value; 1,000,000 shares authorized, Series A, 4,250 shares designated, and 0 shares issued and outstanding as of March 31, 2023 and December 31, 2022 | 0 | 0 |
Common stock, $0.001 par value; 150,000,000 shares authorized, 43,289,969 and 42,832,231 shares issued and outstanding, respectively, as of March 31, 2023 and December 31, 2022 | 43 | 43 |
Additional paid-in capital | 619,227 | 611,739 |
Accumulated other comprehensive loss, net of taxes | (534) | (679) |
Accumulated deficit | (260,629) | (246,915) |
Total shareholders’ equity | 358,107 | 364,188 |
Total liabilities and shareholders’ equity | $ 446,470 | $ 450,229 |